{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"11.7","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"}],"units":"Participants"}],"title":"Since Diagnosis for Living Participants: Eligible"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"11.2","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"}],"units":"Participants"}],"title":"Since Diagnosis for Living Participants: Not Eligible"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"8.5","value":"3.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"Since Diagnosis to Lost to Follow-up: Eligible"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"8.6","value":"2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"Since Diagnosis to Lost to Follow-up: Not Eligible"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"9.9","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"169"}],"units":"Participants"}],"title":"Since Diagnosis to Death: Eligible"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"10","value":"1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"256"}],"units":"Participants"}],"title":"Since Diagnosis to Death: Not Eligible"}],"denoms":[{"counts":[{"groupId":"OG000","value":"922"}],"units":"Participants"}],"description":"Duration of treatment was defined with respect to selected lines or regimens of interest, considering the time elapsed from each treatment initiation to discontinuation, and censoring participants who lost to follow-up before discontinuation. Duration of treatment was classified by participants eligibility- eligible/not eligible for transplantation. The deaths occurred after treatment initiation to end of study are reported in categories 'Since Diagnosis to Death-Eligible and Not Eligible'.","dispersionType":"Full Range","groups":[{"description":"Participants with MM were observed retrospectively since the diagnosis up to death or lost to follow-up within the eligibility window of time (between January 1, 2008 and December 31, 2016), in this study.","id":"OG000","title":"Multiple Myeloma Participants"}],"paramType":"MEDIAN","populationDescription":"All participants eligible for analyses who had non-missing observations were analyzed. Number analyzed is the number of participants with data available for given category.","reportingStatus":"POSTED","timeFrame":"From treatment initiation up to discontinuation of treatment or lost to follow-up, whichever occurs first up to the end of this study (up to 11.7 years)","title":"Duration of Treatment","type":"SECONDARY","unitOfMeasure":"years"}